WO2016181220A2 - Compositions thérapeutiques et méthodes d'utilisation de ces compositions - Google Patents

Compositions thérapeutiques et méthodes d'utilisation de ces compositions Download PDF

Info

Publication number
WO2016181220A2
WO2016181220A2 PCT/IB2016/000723 IB2016000723W WO2016181220A2 WO 2016181220 A2 WO2016181220 A2 WO 2016181220A2 IB 2016000723 W IB2016000723 W IB 2016000723W WO 2016181220 A2 WO2016181220 A2 WO 2016181220A2
Authority
WO
WIPO (PCT)
Prior art keywords
component
group
composition
curcumin
graph
Prior art date
Application number
PCT/IB2016/000723
Other languages
English (en)
Other versions
WO2016181220A3 (fr
Inventor
Gene H. Zaid
Thomas W. BURGOYNE
Original Assignee
Ions Pharmaceutical S.À R.L.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/721,011 external-priority patent/US9402834B2/en
Priority claimed from PCT/US2015/055968 external-priority patent/WO2016064676A1/fr
Application filed by Ions Pharmaceutical S.À R.L. filed Critical Ions Pharmaceutical S.À R.L.
Priority to US15/338,020 priority Critical patent/US20170042867A1/en
Priority to US15/337,795 priority patent/US10092550B2/en
Priority to US15/337,987 priority patent/US9907786B2/en
Priority to US15/337,957 priority patent/US20170105976A1/en
Priority to US15/337,882 priority patent/US20170105975A1/en
Publication of WO2016181220A2 publication Critical patent/WO2016181220A2/fr
Publication of WO2016181220A3 publication Critical patent/WO2016181220A3/fr
Priority to US15/486,406 priority patent/US20170216222A1/en
Priority to US15/826,101 priority patent/US20180078535A1/en
Priority to US16/213,774 priority patent/US10471049B2/en
Priority to US16/541,665 priority patent/US10576067B2/en
Priority to US16/541,626 priority patent/US10532043B2/en
Priority to US16/541,695 priority patent/US10507200B1/en
Priority to US16/724,979 priority patent/US10751330B2/en
Priority to US16/724,935 priority patent/US10744124B2/en
Priority to US17/000,164 priority patent/US11266634B2/en
Priority to US17/589,060 priority patent/US11951099B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/121—Ketones acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Compositions de traitement thérapeutique humain comprenant au moins deux constituants parmi les suivants : un constituant curcumine, un constituant harmine et un constituant isovanilline, et de préférence, les trois en association. Lesdits agents sont efficaces pour le traitement d'états pathologiques humains, en particulier de cancers affectant l'homme.
PCT/IB2016/000723 2014-10-21 2016-04-20 Compositions thérapeutiques et méthodes d'utilisation de ces compositions WO2016181220A2 (fr)

Priority Applications (15)

Application Number Priority Date Filing Date Title
US15/337,882 US20170105975A1 (en) 2014-10-21 2016-10-28 Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof
US15/337,957 US20170105976A1 (en) 2014-10-21 2016-10-28 Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof
US15/338,020 US20170042867A1 (en) 2014-10-21 2016-10-28 Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof
US15/337,795 US10092550B2 (en) 2014-10-21 2016-10-28 Therapeutic compositions containing curcumin, harmine, and isovanillin components, and methods of use thereof
US15/337,987 US9907786B2 (en) 2014-10-21 2016-10-28 Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof
US15/486,406 US20170216222A1 (en) 2014-10-21 2017-04-13 Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof
US15/826,101 US20180078535A1 (en) 2014-10-21 2017-11-29 Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof
US16/213,774 US10471049B2 (en) 2014-10-21 2018-12-07 Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof
US16/541,695 US10507200B1 (en) 2014-10-21 2019-08-15 Therapeutics compositions containing harmine and isovanillin components, and methods of use thereof
US16/541,665 US10576067B2 (en) 2014-10-21 2019-08-15 Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof
US16/541,626 US10532043B2 (en) 2014-10-21 2019-08-15 Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof
US16/724,935 US10744124B2 (en) 2014-10-21 2019-12-23 Human therapeutic agents
US16/724,979 US10751330B2 (en) 2014-10-21 2019-12-23 Human therapeutic agents
US17/000,164 US11266634B2 (en) 2014-10-21 2020-08-21 Methods for treating melanoma with human therapeutic agents
US17/589,060 US11951099B2 (en) 2014-10-21 2022-01-31 Methods for treating plasma cell neoplasm with human therapeutic agents

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201562161090P 2015-05-13 2015-05-13
US62/161,090 2015-05-13
US14/721,011 2015-05-26
US14/721,011 US9402834B2 (en) 2014-10-21 2015-05-26 Human therapeutic agents
US201562184051P 2015-06-24 2015-06-24
US62/184,051 2015-06-24
PCT/US2015/055968 WO2016064676A1 (fr) 2014-10-21 2015-10-16 Agents thérapeutiques humains
USPCT/US2015/055968 2015-10-16

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US14/721,011 Continuation-In-Part US9402834B2 (en) 2014-10-21 2015-05-26 Human therapeutic agents
PCT/US2015/055968 Continuation-In-Part WO2016064676A1 (fr) 2014-10-21 2015-10-16 Agents thérapeutiques humains

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US14/721,011 Continuation US9402834B2 (en) 2014-10-21 2015-05-26 Human therapeutic agents
US15/337,795 Continuation US10092550B2 (en) 2014-10-21 2016-10-28 Therapeutic compositions containing curcumin, harmine, and isovanillin components, and methods of use thereof
US15/337,987 Continuation US9907786B2 (en) 2014-10-21 2016-10-28 Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof

Publications (2)

Publication Number Publication Date
WO2016181220A2 true WO2016181220A2 (fr) 2016-11-17
WO2016181220A3 WO2016181220A3 (fr) 2016-12-29

Family

ID=57248993

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2016/000723 WO2016181220A2 (fr) 2014-10-21 2016-04-20 Compositions thérapeutiques et méthodes d'utilisation de ces compositions

Country Status (2)

Country Link
TW (1) TW201713323A (fr)
WO (1) WO2016181220A2 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9907786B2 (en) 2014-10-21 2018-03-06 Ions Pharmaceutical S.À R.L. Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof
US10092550B2 (en) 2014-10-21 2018-10-09 Ions Pharmaceutical S.À R.L. Therapeutic compositions containing curcumin, harmine, and isovanillin components, and methods of use thereof
US10947253B2 (en) 2019-08-05 2021-03-16 Ankh Life Sciences Limited Fused polycyclic dimers
CN114671779A (zh) * 2022-03-15 2022-06-28 温州医科大学 含环戊酮片段的化合物及其作为抗肿瘤药物的应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240000742A1 (en) * 2020-12-17 2024-01-04 Mien-Chie Hung Method for treating lung cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8039025B1 (en) 2010-10-15 2011-10-18 Life Plus, LLC Methods and dosage forms for the treatment of human cancers
US8735154B2 (en) 2006-10-30 2014-05-27 The University Of Kansas Templated islet cells and small islet cell clusters for diabetes treatment

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2869540B1 (fr) * 2004-04-30 2008-05-16 Centre Nat Rech Scient Cnrse Compositions pharmaceutiques contenant des derives de b-carboline, et leur utilisation pour le traitement des cancers
CN100553628C (zh) * 2005-08-25 2009-10-28 中国人民解放军军事医学科学院放射与辐射医学研究所 2-溴-异香兰素在制备抗癌和/或辐射、化疗增敏药物中的应用
WO2008150899A1 (fr) * 2007-05-29 2008-12-11 Emory University Thérapies combinées pour le traitement du cancer et des maladies inflammatoires
US20130231360A1 (en) * 2010-04-22 2013-09-05 The Brigham And Women S Hospital, Inc. Beta-Carbolines as Inhibitors of Haspin and DYRK Kinases
US20120058208A1 (en) * 2010-09-04 2012-03-08 Synthite Industries Ltd. Synergistic Composition for Enhancing Bioavailability of Curcumin
WO2015006646A1 (fr) * 2013-07-11 2015-01-15 Specialty Nutrition Group, Inc. Compositions comprenant un hydroxytyrosol, une curcumine, et/ou astaxanthine et leur utilisation
WO2016064676A1 (fr) * 2014-10-21 2016-04-28 Genzada Pharmaceuticals Llc Agents thérapeutiques humains

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8735154B2 (en) 2006-10-30 2014-05-27 The University Of Kansas Templated islet cells and small islet cell clusters for diabetes treatment
US8039025B1 (en) 2010-10-15 2011-10-18 Life Plus, LLC Methods and dosage forms for the treatment of human cancers

Non-Patent Citations (20)

* Cited by examiner, † Cited by third party
Title
"Handbook of Pharmaceutical Salts Properties, and Use", 2008
AL-MUDARIS ET AL., ANTICANCER PROPERTIES OF NOVEL SYNTHETIC VANILLIN DERIVATIVES, 2012
ANAND: "Biological Activities of Curcumin and Its Analogues (Congeners) Made By Man and Mother Nature", BIOCHEMICAL PHARMACOLOGY, vol. 76, no. 1, 2008, pages 590 - 1611
BANDHAVKAR, S.: "Cancer stem cells: a metastasizing menace", CANCER MED., 2016
CAMMAROTA, F. ET AL.: "Mesenchymal stem/stromal cells in stromal evolution and cancer progression", STEM CELLS INT., 2016, pages 4824573
DICK, J.E.: "Stem cell concepts renew cancer research", BLOOD, vol. 112, 2008, pages 4793 - 4807, XP009136497, DOI: doi:10.1182/blood-2008-08-077941
DIEHN, M. ET AL.: "Cancer stem cells and radiotherapy: new insights into tumor radioresistance", J. NATL. CANCER INST, vol. 98, 2016, pages 1775 - 1757
DOHERTY, M.R. ET AL.: "Cancer stem cell plasticity drives therapeutic resistance", CANCERS, vol. 8,8, 2016
GHALIB, M.S. ET AL.: "Alterations of Chemotherapeutic Pharmoco inetic Profiles by Drug-Drug Interactions", EXPERT OPIN. DRUG METABL. TOXICOL, vol. 5.2, 2009, pages 109 - 130
HAKKARAINEN, K.M. ET AL.: "Prevalence and Perceived Preventability of Self-Reported Adverse Drug Events .... A Population-Based Survey of 7,099 Adults", PLOS ONE, vol. 8.9, 2013, pages E73166
MERY, B. ET AL.: "Targeting head and neck tumoral stem cells: From biological aspects to therapeutic perspectives", WORLD J STEM CELLS, vol. 8.1, 2016, pages 13 - 21
MWANGI, S.M. ET AL.: "DCAMKL- 1: a new horizon for pancreatic progenitor identification", AM J PHYS- GASTRO LIVER PHYSIOL, vol. 299, 2010, pages G301 - 302
NAKANISHI, Y. ET AL.: "Dclk 1 distinguishes between tumor and normal stem cells in the intestine", NATURE GEN, vol. 45, 2013, pages 98 - 103
PATEL, P.S. ET AL.: "A Study of Potential Adverse Drug-Drug Interactions Among Prescribed Drugs in a Medicine Outpatient Department of a Tertiary Care Teaching Hospital", J. BASIC CLIN PHARM, vol. 5.2, 2014, pages 44 - 48
PONNURANGAM. S. ET AL.: "Quinomycin A targets Notch signaling pathway in pancreatic cancer stem cells", ONCOTARGET, vol. 7.3, 2015, pages 3217 - 3232
PRINCE, M.E. ET AL.: "Cancer stem cells in head and neck squamous cell cancer", J. CLIN. ONCOL., vol. 26.17, 2008, pages 2871 - 2875
SHARMA ET AL.: "Imidazole Derivatives Show Anticancer Potential by Inducing Apoptosis and Cellular Senescence", MED. CHEM. COMMUN., vol. 5, 2014, pages 1751
SHEN ET AL.: "The Pharmacology of Curcumin: Is it the Degradation Products?", TRENDS IN MOLECULAR MEDICINE, vol. 18, no. 2, March 2012 (2012-03-01)
US. OBACH: "Drug-Drug Interactions: An Important Negative Attribute in Drugs", DRUGS TODAY, vol. 39.5, 2003, pages 308 - 338
VISVADER, J.E. ET AL.: "Cancer stem cells: Current status and evolving complexities", CELL STEM CELL., vol. 10, 2012, pages 717 - 728, XP028492658, DOI: doi:10.1016/j.stem.2012.05.007

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9907786B2 (en) 2014-10-21 2018-03-06 Ions Pharmaceutical S.À R.L. Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof
US10092550B2 (en) 2014-10-21 2018-10-09 Ions Pharmaceutical S.À R.L. Therapeutic compositions containing curcumin, harmine, and isovanillin components, and methods of use thereof
US10947253B2 (en) 2019-08-05 2021-03-16 Ankh Life Sciences Limited Fused polycyclic dimers
CN114671779A (zh) * 2022-03-15 2022-06-28 温州医科大学 含环戊酮片段的化合物及其作为抗肿瘤药物的应用
CN114671779B (zh) * 2022-03-15 2023-08-22 温州医科大学 含环戊酮片段的化合物及其作为抗肿瘤药物的应用

Also Published As

Publication number Publication date
TW201713323A (en) 2017-04-16
WO2016181220A3 (fr) 2016-12-29

Similar Documents

Publication Publication Date Title
US10092550B2 (en) Therapeutic compositions containing curcumin, harmine, and isovanillin components, and methods of use thereof
CA2955114C (fr) Compositions comprenant un compose curcumine, un compose harmine et un compose isovanilline
US11266634B2 (en) Methods for treating melanoma with human therapeutic agents
US9402834B2 (en) Human therapeutic agents
WO2016181220A2 (fr) Compositions thérapeutiques et méthodes d'utilisation de ces compositions
US20170042867A1 (en) Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof
US20170105975A1 (en) Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof
US20170216222A1 (en) Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof
US20170105976A1 (en) Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof
BR112017006190B1 (pt) Composições terapêuticas, seus processos de fabricação, e uso das mesmas

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16731962

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16731962

Country of ref document: EP

Kind code of ref document: A2